Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) Net Margin (2017 - 2025)

Integra Lifesciences Holdings' Net Margin history spans 16 years, with the latest figure at 0.39% for Q4 2025.

  • For Q4 2025, Net Margin fell 478.0% year-over-year to 0.39%; the TTM value through Dec 2025 reached 31.58%, down 3115.0%, while the annual FY2025 figure was 31.58%, 3115.0% down from the prior year.
  • Net Margin for Q4 2025 was 0.39% at Integra Lifesciences Holdings, up from 1.34% in the prior quarter.
  • Across five years, Net Margin topped out at 13.3% in Q4 2022 and bottomed at 116.47% in Q2 2025.
  • The 5-year median for Net Margin is 5.05% (2023), against an average of 0.97%.
  • The largest annual shift saw Net Margin skyrocketed 1002bps in 2021 before it tumbled -11351bps in 2025.
  • A 5-year view of Net Margin shows it stood at 11.19% in 2021, then grew by 19bps to 13.3% in 2022, then plummeted by -62bps to 5.0% in 2023, then decreased by -12bps to 4.39% in 2024, then tumbled by -109bps to 0.39% in 2025.
  • Per Business Quant, the three most recent readings for IART's Net Margin are 0.39% (Q4 2025), 1.34% (Q3 2025), and 116.47% (Q2 2025).